{"eventGroups":[{"description":"Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.\n\nPlerixafor : 240 µg/kg subcutaneous injection on the day that the ANC is \\> 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.","id":"EG000","otherNumAffected":29,"otherNumAtRisk":45,"seriousNumAffected":0,"seriousNumAtRisk":45,"title":"Plerixafor + Chemo and G-CSF"}],"frequencyThreshold":"0","otherEvents":[{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":45}],"term":"Nausea"},{"organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":45}],"term":"Bone Pain"},{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":45}],"term":"Diarrhea"},{"organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":45}],"term":"Fatigue"},{"organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":45}],"term":"Hypokalemia"},{"organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":45}],"term":"Lightheadedness"},{"organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":45}],"term":"Headache"},{"organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":45}],"term":"Thrombocytopenia Grade 1/2"},{"organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":45}],"term":"Thrombocytopenia Over Grade 2"},{"organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45}],"term":"Anemia"}]}